Novo’s largest shareholder moved to reshape the company’s board, prompting resignation of multiple independent directors and signaling a shift toward tighter operational oversight amid investor unease over strategy and recent leadership churn. The Novo Nordisk‑related governance changes came after shareholder criticism over the company's pace of response to obesity‑market shifts and recent poor guidance from the maker of Wegovy. BioCentury and other outlets reported the reshuffle as an attempt to reassert industry experience at the board level. Novo’s main shareholder signaled intent to install experienced executives, including a former CEO, to restore strategic focus and calm markets amid royalty and commercial pressures for obesity and diabetes franchises.